Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Enrolling by invitation 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 117Myelodysplastic Syndromes 73Leukemia, Myelomonocytic, Chronic 34Leukemia 30Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Myeloproliferative Disorders 8Lymphoma, Non-Hodgkin 8Lymphoma 8Leukemia, Myelomonocytic, Acute 8Congenital Abnormalities 8Recurrence 7Multiple Myeloma 7Lymphoma, Large B-Cell, Diffuse 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Leukemia, Monocytic, Acute 6Leukemia, Erythroblastic, Acute 6Primary Myelofibrosis 5Lung Neoplasms 5Leukemia, Megakaryoblastic, Acute 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hodgkin Disease 5Hematologic Neoplasms 5Anemia, Refractory, with Excess of Blasts 5Prostatic Neoplasms 4Myelodysplastic-Myeloproliferative Diseases 4Melanoma 4Lymphoma, Follicular 4Pancreatic Neoplasms 3

Interventions

eprenetapopt 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × MDS × Azacitidine × Clear all
NCT03745716 2025-03-18

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

Aprea Therapeutics

Phase 3 Completed
154 enrolled 10 charts

MDS

Data powered by HemOnc (CC BY 4.0) Colophon âš¡